AndhraNews.net
Home » Business News » 2012 » September » September 11, 2012

Basilea reports presentation of new data on investigational anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC


September 11, 2012 - Basel, Switzerland


Basilea Pharmaceutica AG /Basilea reports presentation of new data on investigational anti-infectivesisavuconazole, ceftobiprole and BAL30072 at ICAAC. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Basel, Switzerland, September 11, 2012 - Basilea Pharmaceutica Ltd.(SIX: BSLN)today reported that new data on anti-infectives isavuconazole, ceftobiproleandBAL30072 are being presented at the 2012 Interscience Conference onAntimicrobial Agents and Chemotherapy (ICAAC), taking place from September9 to12, 2012, in San Francisco, USA.

Basilea's Chief Scientific Officer Dr. Laurenz Kellenberger commented: "Therising tide of multidrug-resistant bacteria and the still unacceptably highmortality related to serious infections highlight the urgent need for novelantimicrobials. The data presented at ICAAC further substantiate thepromisingprofiles of these innovative product candidates for addressing this highunmetmedical need."

Key presentations include the following:

Posters on isavuconazole

Isavuconazole (ISA) Pharmacodynamic (PD) Target Determination for C.albicans(CA) in an In Vivo Neutropenic Murine Model of Invasive Candidiasis (IC) -A.Lepak, K. Marchillo,j. Cabezas, D.R. Andes; A-1931

In Vitro Activity of Isavuconazole against Cryptococcus Isolates - A PooledAnalysis from 3 Studies - J.I. Smart, M.E. Jones, L.L. Kovanda; M-331

Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of CYP3A4Substrate Midazolam in Healthy Volunteers - A. Desai, N. Zadeikis, H.Pearlman,D. Kowalski,R. Townsend; A-1936

In Vitro Activity of Isavuconazole against a Worldwide Collection of 237Aspergillus terreus Isolates and Compared with 7 Other Aspergillus ActiveAntifungal Drugs Tested with EUCAST and CLSI Methodology - J.F. Meis, J.W.Mouton, J.P. Bouchara, A. Chakrabarti,P. Gaustad, J.V. Guinea-Ortega, J. Houbraken, R.A. Samson, K. Grif, C.Lass-Floerl, C.H. Klaassen; M-332

Posters on ceftobiprole

%fT > MIC Predicts Probability of Microbiological Outcome in the TreatmentofNosocomial Pneumonia by Ceftobiprole - A.E. Muller, N. Punt, J.W. Mouton;A-624

Monte Carlo Simulations Based on Phase 1 Studies Predict Target AttainmentofCeftobiprole in Nosocomial Pneumonia Patients: A Validation Study - A.Muller,A.H. Schmitt-Hoffmann, N. Punt, J.W. Mouton; A-624a

Posters on BAL30072

In Vitro Activity of BAL30072 against Contemporary Clinical Isolates ofGram-Negative Bacteria (GNB) from New York City includingMultidrug-Resistant (MDR)Isolates - D. Landman, M. Singh, B. El-Imad, E. Miller, T. Win, J. Quale;F-841

Antimicrobial Activity of BAL30072, Alone and in Combination with MeropenemTested Against Gram-Negative Bacteria Causing Serious Infections inHospitalsfrom China, India, Latin America and South East Asia-Pacific - P.R.Rhomberg,K.A. Fedler, R.K. Flamm, R.N. Jones, H.S. Sader; E-193

Comparative Efficacy of BAL30072, Aztreonam, Meropenem and Ceftazidime andEffects of Dose Fractionation in a Murine Thigh Infection Model - J.K.gould, A.Sattar, G.M. Daws, L.J. Payne, J. Spikermann, W. StubbinGs, A.SchmiTt-HOffmanN, M.G.P. Page, P.a. Warn;F-842

Urinary Antibacterial Activity of BAL30072 against Uropathogens After IVAdministration - F.M.E. Wagenlehner, B. Blenk, C. Wagenlehner, H. Blenk,K.G.Naber;A-1285

For further information please visit www.icaac.org.

About isavuconazole

Isavuconazole is a novel intravenous and oral broad-spectrum antifungal. Incollaboration with Astellas Pharma Inc., isavuconazole is beinginvestigated ina phase III program for the treatment of severe invasive andlife-threateningfungal infections. The drug demonstrated excellent in-vitro and in-vivocoverageof a broad range of yeasts (such as Candida species) and molds (such asAspergillus species) as well as less prevalent but often fatal molds suchasZygomycetes spp. It has reliable and predictable dosing, allowing a switchfromIV administration to a convenient once daily oral dose and has thepotential toovercome many of the limitations of current treatment options.

About ceftobiprole

Ceftobiprole is a novel broad-spectrum antibiotic for the potentialtreatment ofsevere, multidrug-resistant bacterial infections. The drug has activityagainsta wide range of Gram-positive bacteria, including the MRSA 'superbug' andclinically relevant Gram-negative bacteria. Ceftobiprole has met the studyendpoints in several phase III trials and has shown a typical cephalosporinsafety profile. A Marketing Authorization Application has been submitted inEurope through the decentralized procedure.

About BAL30072

BAL30072 is a novel investigational bactericidal sulfactam antibiotic inphaseI, specifically targeting multidrug-resistant Gram-negative bacteria. Theinnovative antibacterial drug has demonstrated broad in-vitro and in-vivocoverage of Gram-negative pathogens including multidrug-resistantPseudomonasaeruginosa and Acinetobacter baumannii. It has robust activity againstcommonstrains of bacteria that produce antibiotic-inactivating enzymes includingextended-spectrum beta-lactamases (ESBL) and metallo-beta-lactamases suchas theNew Delhi metallo-beta-lactamase 1 (NDM-1). In addition, BAL30072 has beenshownto enhance the activity of antibiotics from the penem class.

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, andlisted onthe SIX Swiss Exchange (SIX: BSLN). Through the fully integrated researchanddevelopment operations of its Swiss subsidiary Basilea PharmaceuticaInternational Ltd. ("Basilea") the company focuses on innovativepharmaceuticalproducts in the therapeutic areas of bacterial infections, fungalinfections andoncology, targeting the medical challenge of rising resistance andnon-responseto current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-lookingstatements concerning Basilea Pharmaceutica Ltd. and its business. Suchstatements involve certain known and unknown risks, uncertainties and otherfactors, which could cause the actual results, financial condition,performanceor achievements of Basilea Pharmaceutica Ltd. to be materially differentfromany future results, performance or achievements expressed or implied bysuchforward-looking statements. Basilea Pharmaceutica Ltd. is providing thiscommunication as of this date and does not undertake to update anyforward-looking statements contained herein as a result of new information,futureevents or otherwise.

This press release can be downloaded from www.basilea.com.

Press release (PDF) :http://hugin.info/134390/R/1640346/528063.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

[HUG#1640346]


For further information, please contact:

Media Relations
Peer Nils Schroder, Ph.D.
Head Public Relations &
Corporate Communications
+41 61 606 1102
Email Contact

Investor Relations
Barbara Zink, Ph.D., MBA
Head Corporate Development
+41 61 606 1233
Email Contact

MarketWire

Comment on this story

Share